- Home
- ONCY vs XGN Comparison
ONCY vs XGN Comparison
Compare ONCY & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONCY | XGN |
|---|---|---|
| Founded | 1998 | 2002 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.7M | 110.7M |
| IPO Year | 2002 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ONCY | XGN |
|---|---|---|
| Price | $0.93 | $4.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $7.33 | ★ $8.86 |
| AVG Volume (30 Days) | ★ 1.6M | 288.8K |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $8.12 |
| Revenue Next Year | $2,505.00 | $13.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.71 | $2.59 |
| 52 Week High | $1.51 | $12.23 |
Technical Indicators
Market Signals| Indicator | ONCY | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 52.82 | 57.44 |
| Support Level | $0.90 | $4.11 |
| Resistance Level | $1.06 | $4.85 |
| Average True Range (ATR) | 0.06 | 0.32 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 62.80 | 67.78 |
Price Performance
Historical ComparisonAbout ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.
About XGN Exagen Inc.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.